retatrutide side effects clinical trials trial results Retatrutide Trial – My Endo Consult Retatrutide side effects: what the

The shift in 2025 and 2026 is that two oral GLP-1 options have entered the market for weight loss

Dosing tiers: Oral administration (500 mcg to 1.5 mg/day) targets gut-specific inflammation: IBD, colitis, and intestinal barrier dysfunction

Characteristics of GLP-1RAs GLP-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes and obesity

For patients using the Allurion Program in combination with low-dose GLP-1s, initial data demonstrate increased weight loss with increases in lean body mass and adherence to GLP-1s

Higher-dose formulations of semaglutide (Wegovy, 2.4 mg weekly) and tirzepatide (Zepbound, up to 15 mg weekly) are approved specifically for chronic weight management in non-diabetic patients

Take Our Free GLP-1 Matching Quiz Answer 10 quick questions about your state, budget, and goals